Takeda Pharmaceutical has entered into partnership with biotech Ambys Medicine to advance the latter’s platform and pipeline.
“Ambys will undertake an intense and sustained effort to advance fundamental science and technology, while developing multiple programs aimed at diverse liver disease targets,” said Jeffrey Tong, Ambys CEO and venture partner with Third Rock Ventures.
“We are uniting a broad range of scientific innovators to help lead a new era of discovery and clinical translation for people with severe liver diseases, and we are delighted to join forces with Takeda in this important effort.”
Ambys is pioneering the application of novel modalities, including cell and gene therapy and gain-of-function drug therapy, to meet the urgent need for treatments that restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.
Takeda said this is aligned with its strategy in gastroenterology to focus on the considerable unmet need in liver through significant investment in novel chemistry and cell/gene therapy platforms.
To that end, Takeda has committed $100 million, including participation in the Series A financing. In return, it receives an option to ex-US commercialisation rights for the first four products that reach an investigational new drug application created under the partnership.
If Takeda elects to exercise an option for a product, it will share in 50% of the development costs for any optioned program and will make development and regulatory milestone payments. Ambys retains full US rights.